Previous 10 | Next 10 |
2023-11-07 07:06:52 ET More on Compugen Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen Financial information for Compugen For further details see: Compugen GAAP EPS of -$0.11 misses by $0.02
Compugen Reports Third Quarter 2023 Results PR Newswire Rilvegostomig, AstraZeneca's (LSE/STO/Nasdaq: AZN) PD-1/TIGIT bi-specific derived from Compugen's COM902, has progressed into Phase 3 as adjuvant therapy for biliary tract cancer after resection in combination with chemot...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Compugen Ltd. (CGEN) is expected to report $-0.09 for Q3 2023
2023-11-06 13:12:03 ET Compugen ( NASDAQ: CGEN ) is scheduled to announce Q3 earnings results on Tuesday, November 7th, before market open. The consensus EPS Estimate is -$0.12 and the consensus Revenue Estimate is $2.5M. Over the last 3 months, EPS estimates have seen...
2023-11-06 10:30:08 ET Major earnings expected before the bell on Tuesday include: Air Products and Chemicals ( APD ) Datadog ( DDOG ) D.R. Horton ( DHI ) Emerson Electric ( EMR ) Uber Technologies ( UBER ) For further details see: Notable...
2023-11-03 16:41:59 ET More on Compugen Historical earnings data for Compugen Financial information for Compugen For further details see: Compugen receives non-compliance notice from Nasdaq
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire HOLON, Israel , Nov. 3, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discover...
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer PR Newswire COM503, a potential first-in-class, high affinity anti-IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth ...
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023 PR Newswire HOLON, Israel , Oct. 24, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target...
News, Short Squeeze, Breakout and More Instantly...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...